Slide 1: Immuron CEO presentation at Coffee Microcaps Conference (ASX announcement)
Immuron CEO, Steven Lydeamore presentation at For personal use only Coffee Microcaps Conference Melbourne, Australia, September 22, 2026: Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to advise our Chief Executive Officer, Steven Lydeamore is presenting at the Coffee Microcaps Conference on Tu
Slide 2: Immuron platform technology, IMM-124E and IMM-529
Immuron’s proprietary technology is based on polyclonal immunoglobulins (IgG) derived from engineered hyper-immune bovine colostrum. Immuron has the capability of producing highly specific immunoglobulins to any enteric pathogen and our products are orally active. Bovine IgG can withstand the acidic
Slide 3: IBS background, references and forward-looking statements
Irritable bowel syndrome (IBS) is a common condition where you experience symptoms related to your digestive system. This is sometimes linked to certain foods, lifestyle habits and stress levels or mood. IBS affects around 3 out of every 10 people. Females are more likely than males to be affected.
Slide 4: September 2026 – Steven Lydeamore, CEO
NASDAQ: IMRN ASX: IMC rsonal use only 22 SEPTEMBER 2026 INVESTOR PRESENTATION S t e v e n Ly d e a m o r e - C E O 1
Slide 5: Safe Harbor Statement
SAFE HARBOR STATEMENT C e r t a i n s t a t e m e nt s m a d e i n t h i s p re s e nt a t i o n a re fo r wa rd - l o o k i n g s t a t e m e nt s a n d a re b a s e d o n I m m u ro n ’s c u r re nt ex p e c t a t i o n s , e s t i m a t e s a n d p ro j e c t i o n s . Wo rd s s u c h a s “a nt i
Slide 6: Immuron company and financial snapshot
Immuron Ltd is an Australian integrated biopharmaceutical company with global scale, focused on developing, and commercialising, oral products for the treatment of gut mediated diseases rsonal use only Technology Research & Financial Snapshot Development Global Corporate Platform Safe and potentiall
Slide 7: FY26 Financial Achievements
FY26 Financial Achievements rsonal use only United States Sales Global Sales Australian Sales Revenue Revenue Revenue $1.8m $7.7m $5.8m Up 7% Up 6% Up 10% Up 13% in $USD Gross Profit Margin Net Profit Cash 64.5% $(3.8)m $9.0m 0.9% $1.4m $6.2m1 decline improvement improvement 4 1. $3.0 million was he
Slide 8: FY26 Clinical Achievements and Operational Highlights
FY26 Clinical Achievements and Operational Highlights rsonal use only New U.S. FDA approval Travelan® Department of IMM-529 n=851 trial Defense IND completed subaward Strategic reset Engaged Pullan New product launch aimed at Consulting to in Australia profitability and support partnering reduced ca
Slide 9: FY27 Outlook
FY27 Outlook rsonal use only Continued Travelan® Geographic sales Portfolio expansion sales growth expansion Continued Cash to fund Partnering update improvement in operations through for IMM-529 profitability and FY27 – FY28 reduced cash burn 6
Slide 10: Immuron strategic reset provides clearer path to profitability
Immuron strategic reset provides clearer path to profitability Immuron has taken a strategic decision to partner clinical assets IMM-124E and IMM-529 for development and commercialization. rsonal use only • IMM-124E is eligible for an end of Phase 2 meeting with the U.S. FDA (indication: traveler’s
Slide 11: IMM-529: A First-in-Class Triple-Action CDI Biologic
IMM-529: A First-in-Class Triple-Action CDI Biologic The Opportunity: IMM-529 is an oral, non-systemic biological (hyperimmune bovine colostrum) for treatment and prevention of primary and recurrent Clostridioides difficile infection (CDI). Unlike antibiotics, IMM-529 eliminates rsonal use only the
Slide 12: IMM-529 Market Potential
IMM-529 Market Potential The Disease: C. difficile is the leading cause of healthcare-associated rsonal use only infection causing 400,000 cases and 30,000 deaths in the US annually Disease spectrum: • Mild-to-moderate: Watery persistent diarrhea, cramping • Severe/Pseudomembranous Colitis (PMC): Co
Slide 13: IMM-529 Deal Potential
IMM-529 Deal Potential Licensor / Asset Stage at Year Licensee / Acquirer Licensed Asset Financial terms (public) Status update (as of March 2026) Owner deal rsonal use only Asset sale signed Aug 2024 (public reporting FDA approved (Apr 2023) and commercialized by VOWST (SER-109) indicates deal stru
Slide 14: Institutional Investor Snapshot FY2026
IMMURON LIMITED (ASX:IMC / Nasdaq:IMRN) | Institutional Investor Snapshot FY2026 Revenue Market Cap. Cash Pipeline A$7.7m FY26 A$14.85m A$9.0m 2 Assets +6% YoY 17 September 2026 Partnering focus rsonal use only @30 June 26; 24-month runway Investment Catalysts (12-18 months) Risk / Reward Assessment
Slide 15: Steven Lydeamore contact information
rsonal use only STEVEN LYDEAMORE CHIEF EXECUTIVE OFFICER IMMURON LIMITED CONTACT INFORMATION: EMAIL: STEVE@IMMURON.COM PHONE: AUSTRALIA: +61 438 027 172